Carfilzomib: In Relapsed, or Relapsed and Refractory, Multiple Myeloma

Author： McCormack Paul L.  

Publisher： Adis International

ISSN： 0012-6667

Source： Drugs, Vol.72, Iss.15, 2012-10, pp. : 2023-2032

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Lenalidomide: A Review of its Use in the Treatment of Relapsed or Refractory Multiple Myeloma

By Scott Lesley J.   Lyseng-Williamson Katherine A.  

Drugs, Vol. 71, Iss. 5, 2011-03 ,pp. : 625-649

Adis International

Access to resources Recommend Favorite

High-dose tamoxifen is not a feasible option in patients with relapsed or refractory multiple myeloma

By  

Inpharma, Vol. 1, Iss. 1439, 2004-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Predictors of survival outcomes in phase 1 relapsed or refractory multiple myeloma patients

By Barbee Meagan S.   Nooka Ajay   Kaufman Jonathan L.   Kim Sungjin   Chen Zhengjia   Heffner Leonard T.   Lonial Sagar   Harvey R. Donald  

Cancer, Vol. 121, Iss. 6, 2015-03 ,pp. : 853-862

Blackwell Publishing

Access to resources Recommend Favorite

Oblimersen feasible in relapsed multiple myeloma

By  

Inpharma, Vol. 1, Iss. 1489, 2005-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Pegylated Liposomal Doxorubicin: A Review of its Use in the Treatment of Relapsed or Refractory Multiple Myeloma

By Plosker Greg L.  

Drugs, Vol. 68, Iss. 17, 2008-01 ,pp. : 2535-2551

Adis International

Access to resources Recommend Favorite